Midostaurin

Major

Midostaurin Relugolix Orgovyx Increased relugolix exposure Details Midostaurin Simvastatin Flolipid Increased OATP1B1 substrate exposure Details Midostaurin Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Midostaurin Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Midostaurin Atorvastatin Atorvaliq Increased OATP1B1 substrate exposure Details Midostaurin Digoxin Cardoxin® Increased digoxin exposure Details Midostaurin Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Midostaurin Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Midostaurin Irinotecan Camptosar Increased BCRP substrate exposure Details Midostaurin Irinotecan Injection Camptosar Increased BCRP substrate exposure Details Midostaurin Ketoconazole Topical Extina® Foam Increased midostaurin exposure Details Midostaurin Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Midostaurin Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Midostaurin Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Midostaurin Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Midostaurin Letermovir Injection Prevymis Increased OATP1B1 substrate exposure Details Midostaurin Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Midostaurin Methotrexate Jylamvo Increased BCRP and OATP1B1 substrate exposure Details Midostaurin Methotrexate Injection Abitrexate® Increased BCRP and OATP1B1 substrate exposure Details Midostaurin Adagrasib Krazati Increased CYP3A4 substrate exposure Details Midostaurin Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Midostaurin Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Midostaurin Apalutamide Erleada Decreased midostaurin exposure Details Midostaurin Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Midostaurin Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Midostaurin Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Midostaurin Boceprevir Increased midostaurin exposure Details Midostaurin Bosentan Increased OATP1B1 substrate exposure Details Midostaurin Bupropion Aplenzin Decreased CYP2B6-substrate exposure Details Midostaurin Carbamazepine Carbatrol Decreased midostaurin exposure Details Midostaurin Ceritinib Zykadia Increased exposure of CYP3A substrate Details Midostaurin Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Midostaurin Clarithromycin Biaxin Increased midostaurin exposure Details Midostaurin Cobicistat Tybost Increased midostaurin exposure Details Midostaurin Conivaptan Vaprisol Increased midostaurin exposure Details Midostaurin Crizotinib Xalkori Increased exposure of the CYP3A substrate Details Midostaurin Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Midostaurin Daridorexant Increased CYP3A4 substrate with NTI exposure Details Midostaurin Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Elagolix Orilissa Increased OATP1B1 substrate exposure Details